Lupin Diagnostics Limited (LDL), a wholly owned subsidiary of global pharmaceutical leader Lupin Limited, has achieved full NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation for all its greenfield laboratories across India.

“This milestone is a reflection of our unwavering commitment to patient care and our mission to support healthier lives,” said Ravindra Kumar, CEO of Lupin Diagnostics. “With 27 greenfield labs nationwide, we are ensuring timely, reliable, and evidence-based diagnostics to empower both patients and healthcare providers. Our focus remains on continuous innovation and raising the standards of healthcare.”

This achievement underlines Lupin Diagnostics’ strict adherence to high-quality standards and robust quality control protocols, reinforcing the company’s dedication to delivering accurate and trustworthy diagnostic services.

Lupin Diagnostics has also earned multiple accolades that highlight its patient-first approach and industry leadership. These include:

‘Patient-Centric Diagnostic Laboratories Company of the Year’ at the IHW 3rd Patients First Award 2024

‘Emerging Diagnostics Chain of the Year’ at the Diagnostics Innovation and Excellence Awards 2024 by Voice of Healthcare

‘Pathology Lab of the Year’ (National Category) at the ET Healthcare Awards in both 2022 and 2024

These honors further cement LDL’s reputation as a trusted and pioneering player in India’s diagnostics landscape.